Abstract
We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
| Original language | English |
|---|---|
| Pages (from-to) | 543-551 |
| Number of pages | 9 |
| Journal | Annals of Hematology |
| Volume | 91 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2012 Apr 1 |
Fingerprint
Keywords
- CVP
- First-line
- Immunochemotherapy
- Marginal zone lymphoma
- Rituximab
ASJC Scopus subject areas
- Hematology
Cite this
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy : Consortium for Improving Survival of Lymphoma (CISL) study. / Kang, Hye Jin; Kim, Won Seog; Kim, Seok Jin; Lee, Je Jung; Yang, Deok Hwan; Kim, Jin Seok; Lee, Se Ryeon; Lee, Gyeong Won; Kim, Hyo Jung; Kim, Ho Young; Oh, Sung Yong; Kim, Hugh Chul; Eom, Hyeon Seok; Chung, Jooseop; Park, Jinny; Suh, Cheolwon; Ryoo, Baek Yeol.
In: Annals of Hematology, Vol. 91, No. 4, 01.04.2012, p. 543-551.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy
T2 - Consortium for Improving Survival of Lymphoma (CISL) study
AU - Kang, Hye Jin
AU - Kim, Won Seog
AU - Kim, Seok Jin
AU - Lee, Je Jung
AU - Yang, Deok Hwan
AU - Kim, Jin Seok
AU - Lee, Se Ryeon
AU - Lee, Gyeong Won
AU - Kim, Hyo Jung
AU - Kim, Ho Young
AU - Oh, Sung Yong
AU - Kim, Hugh Chul
AU - Eom, Hyeon Seok
AU - Chung, Jooseop
AU - Park, Jinny
AU - Suh, Cheolwon
AU - Ryoo, Baek Yeol
PY - 2012/4/1
Y1 - 2012/4/1
N2 - We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
AB - We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m 2, cyclophosphamide 750 mg/m 2 and vincristine 1.4 mg/m 2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1-5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77-98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
KW - CVP
KW - First-line
KW - Immunochemotherapy
KW - Marginal zone lymphoma
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=84860805905&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860805905&partnerID=8YFLogxK
U2 - 10.1007/s00277-011-1337-6
DO - 10.1007/s00277-011-1337-6
M3 - Article
VL - 91
SP - 543
EP - 551
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 4
ER -